Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months

Results of a phase 2 observational extension

Jun-Ichi Kira, Yasuto Itoyama, Seiji Kikuchi, Qi Hao, Takayoshi Kurosawa, Kazuo Nagato, Isao Tsumiyama, Philipp von Rosenstiel, Lixin Zhang-Auberson, Takahiko Saida

研究成果: ジャーナルへの寄稿記事

33 引用 (Scopus)

抄録

Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod.Methods: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to fingolimod 1.25 mg or 0.5 mg. During the extension, all patients were switched to open-label fingolimod 0.5 mg.Results: Magnetic resonance imaging (MRI) and relapse outcomes were maintained or improved in patients treated with fingolimod for 12 months versus those treated for 6 months. No new safety events were reported over 12 months of treatment. Infections occurred in similar proportions of continuously treated and switched patients, while cardiac and liver adverse events occurred in fewer continuously treated than switched patients. Four patients were aquaporin-4 (AQP4) antibody-positive, three of whom showed rapid disease exacerbations within 10 days of fingolimod initiation.Conclusion: Continuous fingolimod treatment for up to 12 months was associated with maintained or improved efficacy and a manageable safety profile, consistent with that previously seen. Results in a small number of patients suggest lack of benefit in AQP4 antibody-positive patients. Meaningful statistical interpretation was limited by the small sample size in each treatment group, owing to the number of patients who completed the core study.Trial registration: ClinicalTrials.gov NCT00670449.

元の言語英語
記事番号21
ジャーナルBMC neurology
14
発行部数1
DOI
出版物ステータス出版済み - 1 29 2014

Fingerprint

Multiple Sclerosis
Aquaporin 4
Therapeutics
Safety
Placebos
Fingolimod Hydrochloride
Relapsing-Remitting Multiple Sclerosis
Antibodies
Patient Safety
Sample Size
Disease Progression
Magnetic Resonance Imaging
Recurrence
Liver
Infection

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

これを引用

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months : Results of a phase 2 observational extension. / Kira, Jun-Ichi; Itoyama, Yasuto; Kikuchi, Seiji; Hao, Qi; Kurosawa, Takayoshi; Nagato, Kazuo; Tsumiyama, Isao; von Rosenstiel, Philipp; Zhang-Auberson, Lixin; Saida, Takahiko.

:: BMC neurology, 巻 14, 番号 1, 21, 29.01.2014.

研究成果: ジャーナルへの寄稿記事

Kira, J-I, Itoyama, Y, Kikuchi, S, Hao, Q, Kurosawa, T, Nagato, K, Tsumiyama, I, von Rosenstiel, P, Zhang-Auberson, L & Saida, T 2014, 'Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: Results of a phase 2 observational extension', BMC neurology, 巻. 14, 番号 1, 21. https://doi.org/10.1186/1471-2377-14-21
Kira, Jun-Ichi ; Itoyama, Yasuto ; Kikuchi, Seiji ; Hao, Qi ; Kurosawa, Takayoshi ; Nagato, Kazuo ; Tsumiyama, Isao ; von Rosenstiel, Philipp ; Zhang-Auberson, Lixin ; Saida, Takahiko. / Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months : Results of a phase 2 observational extension. :: BMC neurology. 2014 ; 巻 14, 番号 1.
@article{37c89017a812411e88fb536a9a57931d,
title = "Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: Results of a phase 2 observational extension",
abstract = "Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod.Methods: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to fingolimod 1.25 mg or 0.5 mg. During the extension, all patients were switched to open-label fingolimod 0.5 mg.Results: Magnetic resonance imaging (MRI) and relapse outcomes were maintained or improved in patients treated with fingolimod for 12 months versus those treated for 6 months. No new safety events were reported over 12 months of treatment. Infections occurred in similar proportions of continuously treated and switched patients, while cardiac and liver adverse events occurred in fewer continuously treated than switched patients. Four patients were aquaporin-4 (AQP4) antibody-positive, three of whom showed rapid disease exacerbations within 10 days of fingolimod initiation.Conclusion: Continuous fingolimod treatment for up to 12 months was associated with maintained or improved efficacy and a manageable safety profile, consistent with that previously seen. Results in a small number of patients suggest lack of benefit in AQP4 antibody-positive patients. Meaningful statistical interpretation was limited by the small sample size in each treatment group, owing to the number of patients who completed the core study.Trial registration: ClinicalTrials.gov NCT00670449.",
author = "Jun-Ichi Kira and Yasuto Itoyama and Seiji Kikuchi and Qi Hao and Takayoshi Kurosawa and Kazuo Nagato and Isao Tsumiyama and {von Rosenstiel}, Philipp and Lixin Zhang-Auberson and Takahiko Saida",
year = "2014",
month = "1",
day = "29",
doi = "10.1186/1471-2377-14-21",
language = "English",
volume = "14",
journal = "BMC Neurology",
issn = "1471-2377",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months

T2 - Results of a phase 2 observational extension

AU - Kira, Jun-Ichi

AU - Itoyama, Yasuto

AU - Kikuchi, Seiji

AU - Hao, Qi

AU - Kurosawa, Takayoshi

AU - Nagato, Kazuo

AU - Tsumiyama, Isao

AU - von Rosenstiel, Philipp

AU - Zhang-Auberson, Lixin

AU - Saida, Takahiko

PY - 2014/1/29

Y1 - 2014/1/29

N2 - Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod.Methods: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to fingolimod 1.25 mg or 0.5 mg. During the extension, all patients were switched to open-label fingolimod 0.5 mg.Results: Magnetic resonance imaging (MRI) and relapse outcomes were maintained or improved in patients treated with fingolimod for 12 months versus those treated for 6 months. No new safety events were reported over 12 months of treatment. Infections occurred in similar proportions of continuously treated and switched patients, while cardiac and liver adverse events occurred in fewer continuously treated than switched patients. Four patients were aquaporin-4 (AQP4) antibody-positive, three of whom showed rapid disease exacerbations within 10 days of fingolimod initiation.Conclusion: Continuous fingolimod treatment for up to 12 months was associated with maintained or improved efficacy and a manageable safety profile, consistent with that previously seen. Results in a small number of patients suggest lack of benefit in AQP4 antibody-positive patients. Meaningful statistical interpretation was limited by the small sample size in each treatment group, owing to the number of patients who completed the core study.Trial registration: ClinicalTrials.gov NCT00670449.

AB - Background: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod.Methods: Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to fingolimod 1.25 mg or 0.5 mg. During the extension, all patients were switched to open-label fingolimod 0.5 mg.Results: Magnetic resonance imaging (MRI) and relapse outcomes were maintained or improved in patients treated with fingolimod for 12 months versus those treated for 6 months. No new safety events were reported over 12 months of treatment. Infections occurred in similar proportions of continuously treated and switched patients, while cardiac and liver adverse events occurred in fewer continuously treated than switched patients. Four patients were aquaporin-4 (AQP4) antibody-positive, three of whom showed rapid disease exacerbations within 10 days of fingolimod initiation.Conclusion: Continuous fingolimod treatment for up to 12 months was associated with maintained or improved efficacy and a manageable safety profile, consistent with that previously seen. Results in a small number of patients suggest lack of benefit in AQP4 antibody-positive patients. Meaningful statistical interpretation was limited by the small sample size in each treatment group, owing to the number of patients who completed the core study.Trial registration: ClinicalTrials.gov NCT00670449.

UR - http://www.scopus.com/inward/record.url?scp=84892956539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892956539&partnerID=8YFLogxK

U2 - 10.1186/1471-2377-14-21

DO - 10.1186/1471-2377-14-21

M3 - Article

VL - 14

JO - BMC Neurology

JF - BMC Neurology

SN - 1471-2377

IS - 1

M1 - 21

ER -